Galectin Therapeutics to Present at the 28th Annual ROTH Conference

NORCROSS, Ga., March 07, 2016 -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces today Peter G. Traber, M.D., the Company’s president, chief executive officer and chief medical officer, will present at the 28^th Annual ROTH Conference on Monday, March 14th, 2016 at 4:00 p.m. Pacific time. The conference is being held at the Ritz-Carlton, Laguna Niguel in Dana Point, California from March 13-16, 2016.

The ROTH Conference presentation will be webcast, and may be found on the company’s website at www.galectintherapeutics.com. The webcast and presentation will be archived on the company's website for 90 days following the event.

About Galectin Therapeutics

Galectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.

Contacts
Jack Callicutt, Chief Financial Officer
(678) 620-3186
[email protected]

LHA
Kim Golodetz
(212) 838-3777
[email protected]

Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc.